{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:21:36Z","timestamp":1788193296009,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018630","name":"Shanghai Municipal People's Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012600","name":"ShanghaiTech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jare.2026.02.013","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:14:03Z","timestamp":1770999243000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting class I HDACs suppresses oncogenic vulnerabilities and potentiates KRAS\/MAPK pathway inhibitors in KRAS-mutant cancers"],"prefix":"10.1016","author":[{"given":"Kexin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0080-5477","authenticated-orcid":false,"given":"Mingyue","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangxuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3572-5269","authenticated-orcid":false,"given":"Chengying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jare.2026.02.013_b0005","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.jare.2026.02.013_b0010","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jare.2026.02.013_b0015","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"8013","key":"10.1016\/j.jare.2026.02.013_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/0008-5472.CAN-24-1093","article-title":"Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL-positive leukemia","volume":"85","author":"Luo","year":"2025","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","article-title":"RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms","volume":"17","author":"Yang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2026.02.013_b0035","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"response and resistance to RAS inhibition in cancer","author":"Ebright","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.02.013_b0040","article-title":"Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer","volume":"9 41","author":"Mohanty","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.jare.2026.02.013_b0045","unstructured":"Frizzled-8 integrates Wnt-11 and Transforming Growth Factor-b Signaling in Prostate Cancer."},{"issue":"2","key":"10.1016\/j.jare.2026.02.013_b0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0060","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.02.013_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.jare.2026.02.013_b0070","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41416-019-0473-y","article-title":"A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment","volume":"120","author":"Lim","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0075","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.jare.2026.02.013_b0080","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1021\/acs.jmedchem.2c01985","article-title":"Design and synthesis of triazole-containing HDAC inhibitors that induce antitumor effects and immune response","volume":"66","author":"Sun","year":"2023","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-025-00605-y","article-title":"IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response","volume":"14","author":"Yao","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jare.2026.02.013_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2020.100576","article-title":"Synergistic effect of 1,3,6-trihydroxy-4,5,7-trichloroxanthone in combination with doxorubicin on b-cell lymphoma cells and its mechanism of action through molecular docking","volume":"92","author":"Miladiyah","year":"2020","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jare.2026.02.013_b0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res"},{"issue":"12","key":"10.1016\/j.jare.2026.02.013_b0105","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/JTO.0000000000000007","article-title":"Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression","volume":"8","author":"Guin","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.jare.2026.02.013_b0110","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3324\/haematol.2019.223024","article-title":"RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS","volume":"105","author":"Seibold","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jare.2026.02.013_b0115","article-title":"Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations","volume":"5","author":"Fukuda","year":"2024","journal-title":"Cell Rep Med"},{"issue":"10","key":"10.1016\/j.jare.2026.02.013_b0120","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","article-title":"c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer","volume":"23","author":"Nebbioso","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.02.013_b0125","doi-asserted-by":"crossref","unstructured":"Kong L. R., Ong R. W., Tan T. Z., Mohamed Salleh N. A. B., Thangavelu M., Chan J. V., et al., Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nat Commun. 11 1 (2020) 2086. DOI:10.1038\/s41467-020-15608-y.","DOI":"10.1038\/s41467-020-15608-y"},{"issue":"8","key":"10.1016\/j.jare.2026.02.013_b0130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41568-023-00579-1","article-title":"Insights into recent findings and clinical application of YAP and TAZ in cancer","volume":"23","author":"Franklin","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.jare.2026.02.013_b0135","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ccell.2017.09.007","article-title":"A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-yap axis in pancreatic cancer","volume":"32","author":"Mello","year":"2017","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.jare.2026.02.013_b0140","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41418-024-01326-1","article-title":"Determinants of p53 DNA binding, gene regulation, and cell fate decisions","volume":"31","author":"Fischer","year":"2024","journal-title":"Cell Death Differ"},{"issue":"14","key":"10.1016\/j.jare.2026.02.013_b0145","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.02.013_b0150","article-title":"Targeting mutant p53 for cancer treatment: moving closer to clinical use?","volume":"14 18","author":"Duffy","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2026.02.013_b0155","doi-asserted-by":"crossref","unstructured":"Glimmers of Hope for Targeting p53. Cancer Discov. 12 8 (2022) Of5. DOI:10.1158\/2159-8290.Cd-nd2022-0009.","DOI":"10.1158\/2159-8290.CD-ND2022-0009"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0160","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-019-11045-8","article-title":"\u03b2-arrestin1\/YAP\/mutant p53 complexes orchestrate the endothelin a receptor signaling in high-grade serous ovarian cancer","volume":"10","author":"Tocci","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jare.2026.02.013_b0170","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from invitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40164-023-00466-3","article-title":"Targeting ST8SIA6-AS1 counteracts KRAS(G12C) inhibitor resistance through abolishing the reciprocal activation of PLK1\/c-Myc signaling","volume":"12","author":"Wang","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jare.2026.02.013_b0180","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits hippo-dependent and RAS-MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat Cancer"},{"issue":"21","key":"10.1016\/j.jare.2026.02.013_b0185","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1021\/acs.jmedchem.4c01393","article-title":"Pan-transcriptional enhanced associated domain palmitoylation pocket covalent inhibitor","volume":"67","author":"Kim","year":"2024","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.jare.2026.02.013_b0190","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-17-3487","article-title":"YAP\/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC","volume":"78","author":"Choi","year":"2018","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jare.2026.02.013_b0195","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","article-title":"Genome-wide association between YAP\/TAZ\/TEAD andAP-1 at enhancers drives oncogenic growth","volume":"17","author":"Zanconato","year":"2015","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jare.2026.02.013_b0200","doi-asserted-by":"crossref","unstructured":"Gallenne T., Ross K. N., Visser N. L., Salony, Desmet C. J., Wittner B. S., et al., Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 8 13 (2017) 20572-20587. DOI:10.18632\/oncotarget.16244.","DOI":"10.18632\/oncotarget.16244"},{"issue":"6","key":"10.1016\/j.jare.2026.02.013_b0205","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jare.2026.02.013_b0210","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.devcel.2010.11.012","article-title":"The crumbs complex couples cell density sensing to hippo-dependent control of the TGF-\u03b2-SMAD pathway","volume":"19","author":"Varelas","year":"2010","journal-title":"Dev Cell"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0215","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1038\/s41467-022-34889-z","article-title":"Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer","volume":"13","author":"Adua","year":"2022","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.jare.2026.02.013_b0220","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.jare.2026.02.013_b0225","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.02.013_b0230","article-title":"Efficacy and safety profile of histone deacetylase inhibitors for metastatic breast cancer: a meta-analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jare.2026.02.013_b0235","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2009","journal-title":"Cancer Lett"},{"issue":"17","key":"10.1016\/j.jare.2026.02.013_b0240","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"Yardley","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jare.2026.02.013_b0245","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","article-title":"Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation","volume":"33","author":"Blagitko-Dorfs","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jare.2026.02.013_b0250","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/s41418-018-0080-0","article-title":"A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment","volume":"25","author":"Shen","year":"2018","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.jare.2026.02.013_b0255","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.jare.2026.02.013_b0260","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","article-title":"MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor","volume":"121","author":"Chakraborty","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jare.2026.02.013_b0265","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.devcel.2010.10.015","article-title":"Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells","volume":"19","author":"LeBoeuf","year":"2010","journal-title":"Dev Cell"},{"issue":"4","key":"10.1016\/j.jare.2026.02.013_b0270","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cell.2008.03.025","article-title":"Acetylation is indispensable for p53 activation","volume":"133","author":"Tang","year":"2008","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.jare.2026.02.013_b0275","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-18-3382","article-title":"HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma","volume":"25","author":"Fai\u00e3o-Flores","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jare.2026.02.013_b0280","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1101\/gad.14.8.981","article-title":"Analysis of p53-regulated gene expression patterns using oligonucleotide arrays","volume":"14","author":"Zhao","year":"2000","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.jare.2026.02.013_b0285","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ncb2936","article-title":"Metabolic control of YAP and TAZ by the mevalonate pathway","volume":"16","author":"Sorrentino","year":"2014","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0290","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","article-title":"KRAS and YAP1 converge to regulate EMT and tumor survival","volume":"158","author":"Shao","year":"2014","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jare.2026.02.013_b0295","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/2159-8290.CD-20-1228","article-title":"Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis","volume":"11","author":"Kim","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0300","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.jare.2026.02.013_b0305","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910581","article-title":"Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer","volume":"11","author":"Yun","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"6","key":"10.1016\/j.jare.2026.02.013_b0310","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.jare.2026.02.013_b0315","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-23-2994","article-title":"TEAD inhibition overcomes YAP1\/TAZ-driven primary and acquired resistance to KRASG12C inhibitors","volume":"83","author":"Edwards","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2026.02.013_b0320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.devcel.2019.07.022","article-title":"A Yap-Myc-Sox2-p53 regulatory network dictates metabolic homeostasis and differentiation in kras-driven pancreatic ductal adenocarcinomas","volume":"51","author":"Murakami","year":"2019","journal-title":"Dev Cell"},{"issue":"23","key":"10.1016\/j.jare.2026.02.013_b0325","article-title":"Transforming growth factor betapromotes inflammation and tumorigenesis in smad4-deficient intestinal epithelium in a YAP-dependent manner","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"22","key":"10.1016\/j.jare.2026.02.013_b0330","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2026.02.013_b0335","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat Cancer"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:12:25Z","timestamp":1777623145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209012322600144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":67,"alternative-id":["S209012322600144X"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.02.013","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting class I HDACs suppresses oncogenic vulnerabilities and potentiates KRAS\/MAPK pathway inhibitors in KRAS-mutant cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}